Tirzepatide (Mounjaro) Pharmacology Podcast
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
4.9 • 773 Ratings
🗓️ 12 January 2023
⏱️ 16 minutes
🧾️ Download transcript
Summary
On this episode I discuss the pharmacology of tirzepatide. I’m appreciative of Derek Borkowski who operates Pyrls for providing a free PDF of the 2023 ADA Diabetes Guidelines when you subscribe for an account at Pyrls.com/rlp – Tirzepatide makes its first appearance in the diabetes guidelines for its ability to promote weight loss.
Tirzepatide is a combination GIP and GLP-1 agonist that is currently indicated for diabetes with reductions of A1C in the range of about 2 points.
Much like GLP-1 agonists, tirzepatide can cause GI upset and other gastrointestinal adverse effects like diarrhea.
Tirzepatide doesn’t have a large number of drug interactions which is nice. Corticosteroids can counteract its blood sugar-lowering effects while sulfonylureas and insulin may significantly increase the risk for hypoglycemia.
Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, Eric Christensen. |
| 0:05.1 | Thank you so much for listening today. Go check out Real Life Pharmacology.com. Get your free 31-page |
| 0:11.2 | PDF on the top 200 drugs. Simply an email to subscribe to our mailing list. We'll get you access to that. |
| 0:18.4 | So a great resource, great refresher if you're taking |
| 0:21.7 | port exams, going through pharmacology courses, or just looking for that little clinical |
| 0:27.0 | refresher. So again, real-life pharmacology.com, sign up for the free Top 200 study guide. |
| 0:34.5 | All right, the drug of the day today is TIRS appetite. |
| 0:44.4 | Brand name of this medication is Monjaro. I have heard pronounced a few different ways, but I believe that is the correct pronunciation. This is a newer diabetes agent. So more specifically, used |
| 0:53.1 | for type 2 diabetes, its classification is |
| 0:57.4 | glucose-dependent insulinotropic polypeptide. That is commonly abbreviated as GIP, and it is a |
| 1:09.5 | combination with a glucagon-like peptide receptor agonist. |
| 1:15.1 | So that is GLP-1. |
| 1:17.2 | So I've talked about GLP-1s extensively in previous podcasts, |
| 1:22.3 | semi-glutide, Lyraglutide, I believe I've covered those for sure. |
| 1:27.6 | So you can go back and get a little bit more depth with that. |
| 1:31.2 | There are quite a few similarities. |
| 1:34.2 | And as far as the adverse effect profile, |
| 1:36.3 | which I'll discuss coming up here, |
| 1:38.4 | it is very, very similar to the gLP ones |
| 1:43.3 | as far as adverse effect profile. |
| 1:45.7 | So mechanistically, what do these two things do? |
| 1:51.1 | So ultimately you're going to end up with increased glucose-dependent insulin release. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.